Omnicell, Inc. — Q2 2018 Form 10-Q
Reporting period: Three and six months ended June 30, 2018. Omnicell provides healthcare medication and supply automation, analytics, and medication-adherence solutions. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Financial performance
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | $188.7 | $181.0 | $371.3 | $329.6 |
| Gross profit / margin | $88.8 / 47% | $78.1 / 43% | $171.2 / 46% | $140.3 / 43% |
| Operating income (loss) / margin | $7.3 / 4% | $(0.7) / approximately 0% | $8.0 / 2% | $(17.3) / (5)% |
| Net income (loss) | $6.6 | $1.9 | $9.3 | $(8.5) |
| Diluted earnings (loss) per share | $0.16 | $0.05 | $0.23 | $(0.23) |
- Q2 revenue rose 4%; first-half revenue rose 13%. Product revenue increased 3% in Q2 and 16% in the first half; services and other revenue increased 6% and 5%, respectively.
- Automation and Analytics revenue grew 7% in Q2 and 14% in the first half. Medication Adherence revenue declined 7% in Q2 but increased 5% for the first half. Management attributed changes partly to installation timing and stronger XT-series sales.
- Gross margin improved, particularly in Automation and Analytics, reflecting product mix and lower XT-series ramp-up costs. Medication Adherence gross margin declined from 32% to 30% in both comparison periods.
- Q2 net income included a $2.5 million contingent gain tied to a settlement agreement associated with the Ateb acquisition. The quarter also included a $0.2 million income tax benefit; first-half tax benefit was $5.0 million.
Cash, debt, and liquidity
- Cash and cash equivalents were $46.2 million at June 30, 2018, up from $32.4 million at December 31, 2017. Working capital was $157.2 million; the current ratio was 1.8:1.
- First-half operating cash flow was $40.7 million, versus $38.9 million a year earlier. Investing activities used $28.1 million, including $15.0 million for property and equipment and $13.1 million for software development. Financing provided $0.6 million; debt repayments were $12.5 million.
- Debt principal outstanding was $204.5 million ($175.0 million term loan and $29.5 million revolver); carrying value net of issuance costs was $198.8 million. The company reported covenant compliance. Its revolving facility commitment was $315 million.
- Management said current cash, expected operating cash flows, employee equity-plan proceeds, and available credit were expected to meet needs for at least the next 12 months.
Changes, outlook, risks, and unusual items
- Compared with the prior-year periods, the company moved from an operating loss to operating income and from a first-half net loss to net income. First-half revenue growth was led by Automation and Analytics; Q2 Medication Adherence revenue softened.
- Prior-year comparisons reflect full retrospective adoption of ASC 606. The new standard changed revenue timing and presentation, including GPO fees as a reduction of revenue and certain commission-cost recognition. Use the adjusted comparative figures in the filing.
- No specific numerical revenue or earnings guidance is provided in the supplied filing text. Management described continued investment in differentiated products, new markets, acquisitions, and partnerships, and cited backlog and current business plans in its liquidity assessment.
- Execution risks include customer installation timing, product acceptance and development, competition, healthcare-provider capital budgets, supply availability, cybersecurity and privacy compliance, foreign-exchange exposure, and integration of acquired businesses. Q2 international revenue was 13% of total.
- Two disclosed lawsuits involve Omnicell or its subsidiary: a product-liability/negligence matter filed in Virginia and a proposed class action alleging Illinois biometric-privacy violations. The company said losses were reasonably possible but not probable, had recorded no accrual, and could not reasonably estimate a loss range.
- At June 30, the company had $77.1 million of minimum operating-lease payments and $56.2 million of non-cancelable purchase commitments. It accrued $3.0 million for a 2018 commercial-group realignment and paid $1.9 million; $1.1 million remained accrued.
- Foreign-currency translation reduced other comprehensive income by $4.4 million in Q2. The company had $104.5 million of debt exposed to interest-rate fluctuations after hedging; it estimated a 1% rate increase would add about $1.0 million of annual interest expense.
Key facts investors should verify
- Whether revenue growth and margin gains persist after accounting for installation timing, product mix, and prior-year XT-series ramp-up effects.
- How much reported earnings benefited from the $2.5 million Ateb-related contingent gain and tax benefits, and whether those items recur.
- Debt repayment, interest-rate exposure, covenant headroom, and actual availability under the revolving facility.
- Developments and potential financial impact of the disclosed lawsuits, privacy requirements, and other contingencies.
- Whether installation capacity, product adoption, and supply-chain execution support management’s stated growth and liquidity expectations.